Karolyn Chamberlin

Rarecells Announces New Clinical Data Showing Superior Sensitivity and Tumor Heterogeneity Detection by Synergistic Combination of ctDNA and ISET® CTC-DNA in Patients with Early-Stage Lung Cancer

NEW YORK and PARIS, September 9th, 2025 (GLOBE NEWSWIRE) – Rarecells, a pioneer in liquid biopsy technologies, today presented new data (poster EP.06.64) at the IASLC 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain, from its BioMolCTC Trial conducted in collaboration with Prof. Filippo Lococo’s team at Policlinico Gemelli in Rome. Circulating Tumor […]

Rarecells Announces New Clinical Data Showing Superior Sensitivity and Tumor Heterogeneity Detection by Synergistic Combination of ctDNA and ISET® CTC-DNA in Patients with Early-Stage Lung Cancer Read More »

Vanity Fair Italy Interviews Rarecells Founder Dr. Patrizia Paterlini

Oncologist Patrizia Paterlini: «I look for tumor cells before the tumor becomes visible, which is why I patented a test that looks for tumor cells in the blood in the very early stages of development»   “I chose research because, as an oncologist, I saw too many patients die—I felt powerless,” says the researcher who

Vanity Fair Italy Interviews Rarecells Founder Dr. Patrizia Paterlini Read More »

Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board

NEW YORK, NY and PARIS, FRANCE – June 18, 2025 Rarecells, Inc., a leader in liquid biopsy technology, is pleased to announce the appointment of Dr. Rita Shaknovich to its Scientific Advisory Board. Dr. Shaknovich brings over 20 years of leadership experience across private industry and academia. She has a distinguished track record of building

Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board Read More »

Press Release: Rarecells, Inc. Appoints Dr. Neil Kurtz to Board of Directors

NEW YORK – (March 26, 2025) – Rarecells, Inc., a pioneering company in liquid biopsy, is pleased to announce the appointment of Dr. Neil Kurtz to its Board of Directors. Dr. Kurtz, a renowned healthcare entrepreneur and executive, brings over 40 years of experience in the pharmaceutical, contract research, post-acute care, and medical diagnostic sectors.

Press Release: Rarecells, Inc. Appoints Dr. Neil Kurtz to Board of Directors Read More »

Press Release: Rarecells announces Appointment of New Director to the Board

NEW YORK, Sept. 6, 2022 /PRNewswire/ — Rarecells, Inc. today announced the appointment of Dr. Neil Gunn, a recognized leader and expert in the diagnostic space, as an independent Board Director. “We are delighted to welcome Neil as Board Director. With his broad understanding of diagnostics and the Liquid Biopsy space he is well-positioned to provide valuable perspectives

Press Release: Rarecells announces Appointment of New Director to the Board Read More »

Scroll to Top

You're one click away from your download !

Please enter the requested information below and click SEND

You're one click away from your download !

Please enter the requested information below and click SEND

You're one click away from your download !

Please enter the requested information below and click SEND